LOGIN  |  REGISTER
Chimerix
Chimerix

LeMaitre Vascular to Participate at Upcoming Investor Conferences in September

August 28, 2025 | Last Trade: US$94.48 0.54 -0.57

BURLINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in four upcoming investor conferences.

2025 Wells Fargo Healthcare Conference

Wednesday, September 3, 2025

Encore Boston Harbor, Everett, MA

Dorian LeBlanc, CFO, will present at 1:30 PM ET

Cantor Global Healthcare Conference

Thursday, September 4, 2025

InterContinental New York Barclay Hotel, New York, NY

Dorian LeBlanc, CFO, will present at 10:55 AM ET

Morgan Stanley 23rd Annual Global Healthcare Conference

Tuesday, September 9, 2025

Sheraton New York Times Square, New York, NY

Dorian LeBlanc, CFO, will present at 3:20 PM ET

Barrington Research Fall Investment Conference (Virtual)

Tuesday, September 16, 2025

Dorian LeBlanc, CFO, time to be announced

About LeMaitre

LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. For more information about the Company, please visit www.lemaitre.com

LeMaitre is a registered trademark of LeMaitre Vascular, Inc.

Viking Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page